Global
   
Include All CSL Behring Country Sites

Newsroom

RSS feed

22/02/2012
Half Year Results announcement for 2011/12
CSL Limited today announced its first half result for period ended 31 December 2011. More.

08/12/2011
CSL partners US agency on key study to prevent common causes of abnormalities in newborns
CSL Limited announced today that it is partnering with the world’s largest health research agency, the US National Institutes of Health (NIH), to study a potential new treatment for the prevention of congenital CMV infection, one of the most common known causes of congenital (i.e., present at birth) abnormalities in the developed world. More.

09/11/2011
CSL wins equal opportunity award for onsite childcare centre
CSL Limited has been recognised as one of Australia’s most outstanding equal opportunity employers by the Federal Government for its work in establishing an innovative onsite childcare centre at its corporate headquarters in Melbourne. More.

19/10/2011
CSL announces A$900m share buy-back
CSL Limited today announced a new on-market buy-back of up to A$900 million of CSL shares. More.

29/09/2011
CSL Biotherapies - Response to News Reports on FDA Inspections
CSL Biotherapies wishes to clarify that it has not received any new letters or warnings from the US Food and Drug Authority (FDA) or the Australian Therapeutic Goods Administration (TGA) concerning its compliance with current Good Manufacturing Practice (cGMP). More.

27/09/2011
CSL Biotherapies - Restricted Supply of BenPen™
CSL Biotherapies has advised hospitals that BenPen™ (Benzylpenicillin) is on restricted supply in Australia and New Zealand until December 2011. More.

06/09/2011
CSL opens $4.8m workplace childcare centre
CSL Limited and the Early Childhood Management Services (ECMS) today proudly opened the Thinking Kids Children’s Centre, an early childhood education and care centre at CSL’s Parkville site in Victoria. More.

17/08/2011
Full Year Results Announcement for 2010/11
CSL Limited today reported a net profit after tax of $941 million for the twelve months ended 30 June 2011, down $112 million or 11% when compared to the prior comparable period. More.

17/08/2011
CSL Announces Changes to the Board
CSL Limited (ASX:CSL) today announced that Chairman, Miss Elizabeth Alexander, AM, and Director, Mr David Simpson, have indicated their intention to retire from the CSL Board of Directors at the conclusion of the Company’s Annual General Meeting on 19 October 2011. More.

18/07/2011
CSL Subsidiary Donates von Willebrand Factor / Factor VIII to World Federation of Hemophilia
CSL Behring gives more than 1 million units of VWD medication via WFH’s Global Alliance for Progress program as part of its 3-year commitment to the organization. More.

22/06/2011
CSL Biotherapies Statement on FDA Warning Letter for GMP issues at Australian Influenza Vaccine Facility
Today the US Food and Drug Administration (FDA) published a Warning Letter issued by its Office of Compliance and Biologics Quality to CSL Biotherapies, a division of CSL Limited. The FDA regulates the manufacture, marketing and distribution of CSL Biotherapies’ influenza vaccine, Afluria®, in the US market. More.

20/05/2011
CSL welcomes historic pandemic agreement and pledges further support for developing countries
CSL Biotherapies welcomes news of a decision by the World Health Assembly to adopt the Pandemic Influenza Preparedness Framework for the Sharing of Influenza Viruses and Access to Vaccines and Other Benefits. More.

20/05/2011
Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference
CSL Limited (ASX:CSL) subsidiary, CSL Behring, today issued a press release regarding advances that it is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with haemophilia A and B. More.

10/03/2011
Press Release - CSL fully supports the ATAGI recommendations for use of influenza vaccine in children
Today, the Australian Technical Advisory Group on Immunisation (ATAGI) has released a statement of advice for immunisation providers regarding the administration of 2011 trivalent seasonal influenza vaccines. More.

16/02/2011
Half-year results announcement for 2010/11
CSL Limited today announced its first half result for period ended 31 December 2010. More.

25/08/2010
Company Statement - Shelf Life Reduction of Panvax® Junior
Ongoing monitoring by both CSL and the TGA of CSL’s Panvax® Junior vaccine has shown a decline in its potency and as a result a 12 month shelf life can no longer be supported. Panvax® Junior is the paediatric presentation of CSL’s 2009 H1N1 (pandemic) influenza vaccine, which is supplied in a single 0.25ml pre-filled syringe. More.

30/07/2010
Update on Seasonal Influenza Vaccination of Children
CSL Limited (CSL) supports the statement made today by the Commonwealth Chief Medical Officer regarding seasonal flu vaccine for young children. More.

15/07/2010
CSL Announces New Biotech Facility
CSL Limited today announced a major biotechnology project at CSL’s manufacturing site in Broadmeadows, Australia. The centrepiece of the project will be the creation of Victoria’s first large scale biotechnology facility for the late stage development of new therapies for cancer, bleeding disorders, inflammation and infection. More.

29/06/2010
Media Statement - CSL receive "Untitled Letter" from FDA
On 24 June 2010, CSL received an “Untitled Letter” from the United States Food and Drug Administration (FDA) relating to a routine inspection it conducted at our Parkville manufacturing facility in April 2010. The inspection related to CSL’s seasonal and pandemic influenza vaccines licensed for use in the United States. More.

01/06/2010
Update on Seasonal Influenza Vaccination of Young Children
CSL Biotherapies (CSL) today notes the Chief Medical Officer’s statement and updated recommendations regarding influenza vaccination for children under 5. More.

23/04/2010
Seasonal influenza vaccine – paediatric adverse events
CSL Biotherapies is aware of reports of a number of adverse events following influenza vaccination of children. CSL is one of several suppliers of influenza vaccine in Australia. More.

16/04/2010
CSL subsidiary Marks World Hemophilia Day with Factor IX Donation to World Federation of Hemophilia
Hemophilia B patients in the developing world will benefit from a recent donation of 1 million international units (IU) of factor IX medication made by CSL Behring to the World Federation of Hemophilia (WFH). More.

30/03/2010
CSL Limited publishes first Corporate Responsibility Report
CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, has released its first Corporate Responsibility Report, combining information about the Company’s economic, social and environmental performance for 2009. More.

>> Prior Archived Newsroom


 

Media Enquiries - CSL Limited
Sharon McHale
Senior Director Public Affairs
Phone: +613 9389 1506
Mobile: +61 409 978 314
Email: sharon.mchale@csl.com.au
45 Poplar Rd, Parkville
Victoria 3052
Australia		Media Enquiries - CSL Behring
Chris Florentz
Phone: +1 610 878 4316
Fax: +1-610-290-9316
Email: Christopher.Florentz@cslbehring.com
1020 First Avenue
PO Box 61501
King of Prussia, PA 19406-0901
USA